Carel Le Roux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/249391/publications.pdf

Version: 2024-02-01

398 papers	23,472 citations	13865 67 h-index	10445 139 g-index
411 all docs	411 docs citations	411 times ranked	17044 citing authors

#	Article	IF	Citations
1	Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity. Annals of Surgery, 2022, 275, 440-447.	4.2	16
2	Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetic Medicine, 2022, 39, e14669.	2.3	15
3	Erythritol and xylitol differentially impact brain networks involved in appetite regulation in healthy volunteers. Nutritional Neuroscience, 2022, 25, 2344-2358.	3.1	5
4	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1-9.	3.6	32
5	Mechanisms of Weight Loss After Obesity Surgery. Endocrine Reviews, 2022, 43, 19-34.	20.1	43
6	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet, The, 2022, 399, 394-405.	13.7	215
7	Effects of glucagonâ€like peptideâ€1 receptor agonists on histopathological and secondary biomarkers of nonâ€alcoholic steatohepatitis: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 337-342.	4.4	4
8	Oromotor and somatic taste reactivity during sucrose meals reveals internal state and stimulus palatability after gastric bypass in rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2022, 322, R204-R218.	1.8	0
9	Myokines in Appetite Control and Energy Balance. , 2022, 1, 26-47.		9
10	Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. Journal of Experimental Medicine, 2022, 219, .	8.5	33
11	Urinary Metabolomic Changes Accompanying Albuminuria Remission following Gastric Bypass Surgery for Type 2 Diabetic Kidney Disease. Metabolites, 2022, 12, 139.	2.9	6
12	State-of-the-art Medical Therapy Versus Roux-en-Y Gastric Bypass Alone for Treatment of Early Diabetic Kidney Disease. , 2022, 32, 768-771.		1
13	Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Review of Clinical Pharmacology, 2022, , 1-17.	3.1	5
14	A Fatty Diet Induces a Jejunal Ketogenesis Which Inhibits Local SGLT1-Based Glucose Transport via an Acetylation Mechanismâ€"Results from a Randomized Cross-Over Study between Iso-Caloric High-Fat versus High-Carbohydrate Diets in Healthy Volunteers. Nutrients, 2022, 14, 1961.	4.1	3
15	Ciliary neurotrophic factor is increased in the plasma of patients with obesity and its levels correlate with diabetes and inflammation indices. Scientific Reports, 2022, 12, 8331.	3.3	3
16	Can Weight Loss Improve the Cardiovascular Outcomes of Patients with Obesity and Obstructive Sleep Apnea?. Hearts, 2022, 3, 54-65.	0.9	2
17	Does Bypass of the Proximal Small Intestine Impact Food Intake, Preference, and Taste Function in Humans? An Experimental Medicine Study Using the Duodenal-Jejunal Bypass Liner. Nutrients, 2022, 14, 2141.	4.1	4
18	The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients, 2022, 14, 2217.	4.1	8

#	Article	IF	Citations
19	The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. EClinicalMedicine, 2022, 49, 101436.	7.1	7
20	Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care, 2022, 45, 2396-2405.	8.6	19
21	Say what you mean, mean what you say: The importance of language in the treatment of obesity. Obesity, 2022, 30, 1189-1196.	3.0	5
22	Surgery for Weight Loss or Health Gain?. Diabetes Care, 2022, 45, 1498-1499.	8.6	0
23	At home and at risk: The experiences of Irish adults living with obesity during the COVID-19 pandemic. EClinicalMedicine, 2022, 51, 101568.	7.1	2
24	Early experience with a nutrition and survivorship clinic in esophageal cancer. Ecological Management and Restoration, 2021, 34, .	0.4	6
25	Dipeptidyl peptidase-4 activity, lipopolysaccharide, C-reactive protein, glucose metabolism, and gut peptides 3 months after bariatric surgery. Surgery for Obesity and Related Diseases, 2021, 17, 113-120.	1.2	3
26	Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish Obese Subjects study. International Journal of Obesity, 2021, 45, 535-546.	3.4	9
27	Exploring patient beliefs and perceptions regarding obesity as a disease, obesity causation and treatment. Irish Journal of Medical Science, 2021, 190, 163-168.	1.5	5
28	The altered enteroendocrine reportoire following roux-en-Y-gastric bypass as an effector of weight loss and improved glycaemic control. Appetite, 2021, 156, 104807.	3.7	20
29	A Pilot Study of Gut-Brain Signaling After Octreotide Therapy for Unintentional Weight Loss After Esophagectomy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e204-e216.	3.6	1
30	COVID-19 alters thinking and management in metabolic diseases. Nature Reviews Endocrinology, 2021, 17, 71-72.	9.6	21
31	Why are adolescents with obesity and diabetes not having bariatric surgery earlier?. Surgery for Obesity and Related Diseases, 2021, 17, 33-35.	1.2	0
32	Exaggerated postprandial GLP-1 secretion following esophagectomy is not associated with gastric emptying and intestinal transit. Ecological Management and Restoration, 2021, 34, .	0.4	1
33	Bariatric Surgery: There Is a Room for Improvement to Reduce Mortality in Patients with Type 2 Diabetes. Obesity Surgery, 2021, 31, 461-463.	2.1	5
34	Metabolic surgery versus conventional therapy in type 2 diabetes. Lancet, The, 2021, 397, 256-257.	13.7	3
35	Other Potential Benefits of the Sleeve: Effects on Body Fat Setpoint. , 2021, , 393-401.		0
36	Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study. Nutrients, 2021, 13, 174.	4.1	17

#	Article	IF	Citations
37	Management of Obesity in Adults with CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 777-790.	6.1	49
38	Methodological issues in assessing change in dietary intake and appetite following gastric bypass surgery: A systematic review. Obesity Reviews, 2021, 22, e13202.	6.5	12
39	Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot doseâ€ranging study. Diabetes, Obesity and Metabolism, 2021, 23, 1311-1321.	4.4	19
40	Liraglutide Does Not Adversely Impact Fatâ€Free Mass Loss. Obesity, 2021, 29, 529-534.	3.0	4
41	Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?. Nutrients, 2021, 13, 762.	4.1	33
42	Bariatric surgery in the treatment of patients with obesity and type 1 diabetes: A retrospective study of clinical data. Diabetes, Obesity and Metabolism, 2021, 23, 1562-1570.	4.4	6
43	Factors Associated with Favorable Changes in Food Preferences After Bariatric Surgery. Obesity Surgery, 2021, 31, 3514-3524.	2.1	13
44	Clinical Impact of Liraglutide as a Treatment of Obesity. Clinical Pharmacology: Advances and Applications, 2021, Volume 13, 53-60.	1.2	21
45	The role of staging laparoscopy in complex bariatric surgery. Clinical Obesity, 2021, 11, e12460.	2.0	0
46	Weight loss with bariatric surgery or behaviour modification and the impact on female obesityâ€related urine incontinence: A comprehensive systematic review and metaâ€analysis. Clinical Obesity, 2021, 11, e12450.	2.0	10
47	Obesity and responsibility: Is it time to rethink agency?. Obesity Reviews, 2021, 22, e13270.	6.5	16
48	An Exploration of the Patient Lived Experience of Remission and Relapse of Type 2 Diabetes Following Bariatric Surgery. Obesity Surgery, 2021, 31, 3919-3925.	2.1	2
49	Understanding the mechanism of how bariatric surgery works is a key component to build the evidence base. Surgery for Obesity and Related Diseases, 2021, 17, 1391-1392.	1.2	0
50	Endoscopic Evaluation and Management of Late Complications After Bariatric Surgery: a Narrative Review. Obesity Surgery, 2021, 31, 4624-4633.	2.1	12
51	Potential gutâ€“brain mechanisms behind adverse mental health outcomes of bariatric surgery. Nature Reviews Endocrinology, 2021, 17, 549-559.	9.6	23
52	The lived experience of patients with obesity: A systematic review and qualitative synthesis. Obesity Reviews, 2021, 22, e13334.	6.5	24
53	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care, 2021, 44, 2438-2444.	8.6	152
54	Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial. Diabetes Care, 2021, 44, e177-e179.	8.6	2

#	Article	IF	Citations
55	Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia, 2021, 64, 2359-2366.	6.3	39
56	â€œYou Are Always at War With Yourselfâ€•The Perceptions and Beliefs of People With Obesity Regarding Obesity as a Disease. Qualitative Health Research, 2021, 31, 2470-2485.	2.1	4
57	Glycemic Control and Metabolic Adaptation in Response to High-Fat versus High-Carbohydrate Dietsâ€”Data from a Randomized Cross-Over Study in Healthy Subjects. Nutrients, 2021, 13, 3322.	4.1	3
58	Meal Patterns and Food Choices of Female Rats Fed a Cafeteria-Style Diet Are Altered by Gastric Bypass Surgery. Nutrients, 2021, 13, 3856.	4.1	7
59	A Comparison of Total Food Intake at a Personalised Buffet in People with Obesity, before and 24 Months after Roux-en-Y-Gastric Bypass Surgery. Nutrients, 2021, 13, 3873.	4.1	11
60	The Impact of CKD on Perioperative Risk and Mortality after Bariatric Surgery. Kidney360, 2021, 2, 236-244.	2.1	7
61	Protocol for a preclinical systematic review and meta-analysis of pharmacological targeting of peroxisome proliferator-activated receptors in experimental renal injury. BMJ Open Science, 2021, 5, e100240.	1.7	3
62	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, The, 2021, 398, 2160-2172.	13.7	74
63	Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110662.	3.2	2
64	Concept of Metabolic Surgery. , 2021, , 1-7.		0
65	Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease. Frontiers in Endocrinology, 2021, 12, 757228.	3.5	4
66	Amylin as a Future Obesity Treatment. Journal of Obesity and Metabolic Syndrome, 2021, 30, 320-325.	3.6	15
67	Evaluation of Heart Rate Variability and Endothelial Function 3ÂMonths After Bariatric Surgery. Obesity Surgery, 2020, 30, 2450-2453.	2.1	6
68	Improvements in diabetic albuminuria and podocyte differentiation following Roux-en-Y gastric bypass surgery. Diabetes and Vascular Disease Research, 2020, 17, 147916411987903.	2.0	24
69	Comment on: Impact of serum uric acid on renal function after bariatric surgery: a retrospective study. Surgery for Obesity and Related Diseases, 2020, 16, 295-298.	1.2	1
70	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia, 2020, 63, 473-485.	6.3	37
71	Continuous Glucose Monitoring of Glycemic Variability During Fasting Post-Sleeve Gastrectomy. Obesity Surgery, 2020, 30, 3721-3729.	2.1	3
72	Doubleâ€blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study. Obesity Science and Practice, 2020, 6, 255-263.	1.9	12

#	Article	IF	Citations
73	Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nature Reviews Nephrology, 2020, 16, 709-720.	9.6	64
74	Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a crossâ€sectional study in a tertiary nephrology centre. Clinical Obesity, 2020, 10, e12402.	2.0	17
75	Comparison of Preoperative Remission Scores and Diabetes Duration Alone as Predictors of Durable Type 2 Diabetes Remission and Risk of Diabetes Complications After Bariatric Surgery: A Post Hoc Analysis of Participants From the Swedish Obese Subjects Study. Diabetes Care, 2020, 43, 2804-2811.	8.6	18
76	â€œI am terrified of something happening to meâ€•The lived experience of people with obesity during the <scp>COVID</scp>â€19 pandemic. Clinical Obesity, 2020, 10, e12406.	2.0	21
77	Parallel assessment of albuminuria and plasma sTNFR1 in people with type 2 diabetes and advanced chronic kidney disease provides accurate prognostication of the risks of renal decline and death. Scientific Reports, 2020, 10, 14852.	3.3	6
78	Effects of acute aerobic, resistance and combined exercises on 24-h glucose variability and skeletal muscle signalling responses in type 1 diabetics. European Journal of Applied Physiology, 2020, 120, 2677-2691.	2.5	12
79	Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?. Frontiers in Endocrinology, 2020, 11, 289.	3.5	28
80	Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease. BMJ Open Diabetes Research and Care, 2020, 8, e001113.	2.8	10
81	Impact of Metabolic Surgery on Renal Injury in Pre-Clinical Models of Diabetic Kidney Disease. Nephron, 2020, 145, 1-10.	1.8	3
82	Simulating the Post-gastric Bypass Intestinal Microenvironment Uncovers a Barrier-Stabilizing Role for FXR. IScience, 2020, 23, 101777.	4.1	6
83	Can Metabolic Surgery Be Used to Improve Access to and Outcomes of Kidney Transplantation?. Obesity, 2020, 28, 2259-2259.	3.0	0
84	Suppression of enteroendocrine cell glucagon-like peptide (GLP)-1 release by fat-induced small intestinal ketogenesis: a mechanism targeted by Roux-en-Y gastric bypass surgery but not by preoperative very-low-calorie diet. Gut, 2020, 69, 1423-1431.	12.1	19
85	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes and Endocrinology,the, 2020, 8, 640-648.	11.4	139
86	Obesity, cardiovascular risk and healthcare resource utilization in the UK. European Journal of Preventive Cardiology, 2020, , 204748732092563.	1.8	17
87	Metabolic dysfunction and diabetes mellitus during long-term follow-up of severe acute pancreatitis: A case-matched study. Pancreatology, 2020, 20, 813-821.	1.1	11
88	Gastric bypass in female rats lowers concentrated sugar solution intake and preference without affecting brief-access licking after long-term sugar exposure. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2020, 318, R870-R885.	1.8	10
89	Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. Frontiers in Endocrinology, 2020, 11, 408.	3.5	19
90	Improving understanding of type 2 diabetes remission: research recommendations from Diabetes UKâ€™s 2019 remission workshop. Diabetic Medicine, 2020, 37, 1944-1950.	2.3	3

#	Article	IF	Citations
91	Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1064-e1074.	3.6	42
92	Patient perceptions and understanding of obesity related endometrial cancer. Gynecologic Oncology Reports, 2020, 32, 100545.	0.6	8
93	Joint international consensus statement for ending stigma of obesity. Nature Medicine, 2020, 26, 485-497.	30.7	468
94	Biography: Carel le Roux. Obesity Surgery, 2020, 30, 2074-2075.	2.1	1
95	The Effect of Metabolic Surgery on the Complications of Diabetes: What Are the Unanswered Questions?. Frontiers in Endocrinology, 2020, 11, 304.	3.5	9
96	Predictors of weight loss after bariatric surgeryâ€"a cross-disciplinary approach combining physiological, social, and psychological measures. International Journal of Obesity, 2020, 44, 2291-2302.	3.4	26
97	Long-term outcomes of bariatric surgery in patients with diabetes. Expert Review of Endocrinology and Metabolism, 2020, 15, 141-146.	2.4	8
98	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ Open, 2020, 10, e034137.	1.9	5
99	The metabolic benefits of different bariatric operations: what procedure to choose?. Endocrine Connections, 2020, 9, R28-R35.	1.9	21
100	Can Bariatric Surgery Improve the Microvascular Complications of Type 2 Diabetes?. , 2020, , 469-477.		0
101	Gastric Bypass: Mechanisms of Functioning. , 2020, , 7-21.		1
102	Simulation of gastric bypass effects on glucose metabolism and non-alcoholic fatty liver disease with the Sleeveballoon device. EBioMedicine, 2019, 46, 452-462.	6.1	11
103	The Association Between Kidney Disease and Diabetes Remission in Bariatric Surgery Patients With Type 2 Diabetes. American Journal of Kidney Diseases, 2019, 74, 761-770.	1.9	20
104	The Role of the Small Bowel in Unintentional Weight Loss after Treatment of Upper Gastrointestinal Cancers. Journal of Clinical Medicine, 2019, 8, 942.	2.4	2
105	Effect of Macronutrient Type and Gastrointestinal Release Site on PYY Response in Normal Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3661-3669.	3.6	5
106	Bariatric Surgery Leads to Shortâ€Term Effects on Sweet Taste Sensitivity and Hedonic Evaluation of Fatty Food Stimuli. Obesity, 2019, 27, 1796-1804.	3.0	27
107	Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery. Obesity Surgery, 2019, 29, 4095-4104.	2.1	23
108	Risk factors for loss of bone mineral density after curative esophagectomy. Archives of Osteoporosis, 2019, 14, 6.	2.4	11

#	Article	IF	Citations
109	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. Metabolism: Clinical and Experimental, 2019, 100, 153960.	3.4	16
110	Comment on: Metabolic surgery improves renal injury independent of weight loss: a meta-analysis. Surgery for Obesity and Related Diseases, 2019, 15, 1020-1023.	1.2	7
111	Fat free mass is positively associated with hunger and energy intake at extremes of obesity. Appetite, 2019, 143, 104444.	3.7	17
112	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 834-844.	11.4	149
113	Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881987540.	3.2	23
114	Impact of intentional weight loss on diabetic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 2338-2341.	4.4	10
115	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Food Preferences and Potential Mechanisms Involved. Current Obesity Reports, 2019, 8, 292-300.	8.4	21
116	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. Diabetes Care, 2019, 42, 1446-1453.	8.6	84
117	The influence of skeletal muscle on appetite regulation. Expert Review of Endocrinology and Metabolism, 2019, 14, 267-282.	2.4	26
118	Changes in gut hormones, glycaemic response and symptoms after oesophagectomy. British Journal of Surgery, 2019, 106, 735-746.	0.3	16
119	Attenuation of satiety gut hormones increases appetitive behavior after curative esophagectomy for esophageal cancer. American Journal of Clinical Nutrition, 2019, 109, 335-344.	4.7	9
120	Vertical sleeve gastrectomy in adolescents reduces the appetitive reward value of a sweet and fatty reinforcer in a progressive ratio task. Surgery for Obesity and Related Diseases, 2019, 15, 194-199.	1.2	10
121	Photo-Assisted Dietary Method Improves Estimates of Dietary Intake Among People with Sleeve Gastrectomy. Obesity Surgery, 2019, 29, 1602-1606.	2.1	4
122	Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in nonâ€surgical and bariatric surgery patients. Diabetes, Obesity and Metabolism, 2019, 21, 1498-1501.	4.4	61
123	Iron and Vitamin D/Calcium Deficiency after Gastric Bypass: Mechanisms Involved and Strategies to Improve Oral Supplement Disposition. Current Drug Metabolism, 2019, 20, 244-252.	1.2	18
124	Treating prediabetes: why and how should we do it?. Minerva Medica, 2019, 110, 52-61.	0.9	31
125	Changes in glycaemic control, blood pressure and lipids 5 years following laparoscopic adjustable gastric banding combined with medical care in patients with type 2 diabetes: a longitudinal analysis. Clinical Obesity, 2018, 8, 151-158.	2.0	17
126	Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. International Journal of Obesity, 2018, 42, 964-973.	3.4	62

#	Article	IF	Citations
127	Optimisation of follow-up after metabolic surgery. Lancet Diabetes and Endocrinology,the, 2018, 6, 487-499.	11.4	37
128	Effect of Bariatric Surgery on CKD Risk. Journal of the American Society of Nephrology: JASN, 2018, 29, 1289-1300.	6.1	87
129	Glycemic Control after Sleeve Gastrectomy and Roux-En-Y Gastric Bypass in Obese Subjects with Type 2 Diabetes Mellitus. Obesity Surgery, 2018, 28, 1461-1472.	2.1	40
130	Integrated insights into the role of alpha-melanocyte stimulatory hormone in the control of food intake and glycaemia. Peptides, 2018, 100, 243-248.	2.4	2
131	Patient profiling for success after weight loss surgery (GO Bypass study): An interdisciplinary study protocol. Contemporary Clinical Trials Communications, 2018, 10, 121-130.	1.1	16
132	The new gold-standard â€" medical gastric bypass. Nature Reviews Endocrinology, 2018, 14, 257-258.	9.6	7
133	EndoBarrierÂ®: a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?. Obesity Surgery, 2018, 28, 1980-1989.	2.1	32
134	Preoperative weight loss with glucagonâ€like peptideâ€1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: <scp>A</scp> longitudinal analysis. Diabetes, Obesity and Metabolism, 2018, 20, 745-748.	4.4	12
135	Validating the association between plasma tumour necrosis factor receptor 1 levels and the presence of renal injury and functional decline in patients with Type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 95-99.	2.3	13
136	Bariatric Surgery for Obesity. Medical Clinics of North America, 2018, 102, 165-182.	2.5	84
137	Sugar Detection Threshold After Laparoscopic Sleeve Gastrectomy in Adolescents. Obesity Surgery, 2018, 28, 1302-1307.	2.1	7
138	Metabolic Effects of Bariatric Surgery. Clinical Chemistry, 2018, 64, 72-81.	3.2	27
139	Detailed Description of Change in Serum Cholesterol Profile with Incremental Weight Loss After Restrictive Bariatric Surgery. Obesity Surgery, 2018, 28, 1351-1362.	2.1	6
140	Measurement of glomerular filtration rate in patients undergoing obesity surgery. BMC Nephrology, 2018, 19, 383.	1.8	11
141	Bariatric Surgery Does Not Affect Food Preferences, but Individual Changes in Food Preferences May Predict Weight Loss. Obesity, 2018, 26, 1879-1887.	3.0	61
142	Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms. Expert Review of Endocrinology and Metabolism, 2018, 13, 251-262.	2.4	33
143	Current and emerging pharmacotherapy for prediabetes: are we moving forward?. Expert Opinion on Pharmacotherapy, 2018, 19, 1663-1673.	1.8	7
144	Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 606-624.	17.8	69

#	Article	IF	Citations
145	Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. Surgery for Obesity and Related Diseases, 2018, 14, 1033-1040.	1.2	41
146	How Ethical Is Our Current Delivery of Care to Patients with Severe and Complicated Obesity?. Obesity Surgery, 2018, 28, 2078-2082.	2.1	13
147	Biliopancreatic Diversion is associated with greater increases in energy expenditure than Roux-en-Y Gastric Bypass. PLoS ONE, 2018, 13, e0194538.	2.5	10
148	Impact of Abdominal Subcutaneous Fat Reduction on Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus. Bariatric Surgical Patient Care, 2018, 13, 25-32.	0.5	1
149	Obesity and healthcare resource utilization: results from Clinical Practice Research Database (CPRD). Obesity Science and Practice, 2018, 4, 409-416.	1.9	17
150	Food Intake and Eating Behavior After Bariatric Surgery. Physiological Reviews, 2018, 98, 1113-1141.	28.8	119
151	Reply: Bariatric surgery and chronic kidney disease: much hope, but proof is still awaited. International Journal of Obesity, 2018, 42, 1534-1534.	3.4	0
152	Prevention Is Better Than Cure: The Next Frontier for Bariatric Surgery?. Annals of Internal Medicine, 2018, 169, 343-344.	3.9	2
153	Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes. Surgery for Obesity and Related Diseases, 2017, 13, 53-57.	1.2	9
154	Unmet need for bariatric surgery. Surgery for Obesity and Related Diseases, 2017, 13, 1052-1056.	1.2	17
155	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet, The, 2017, 389, 1399-1409.	13.7	502
156	Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial. BMJ Open, 2017, 7, e013574.	1.9	24
157	Weight loss after laparoscopic adjustable gastric band and resolution of the metabolic syndrome and its components. International Journal of Obesity, 2017, 41, 902-908.	3.4	14
158	Outcomes of Diabetic Microvascular Complications After Bariatric Surgery. , 2017, , 137-144.		0
159	Roux-En-Y Gastric Bypass and Sleeve Gastrectomy Does Not Affect Food Preferences When Assessed by an Ad libitum Buffet Meal. Obesity Surgery, 2017, 27, 2599-2605.	2.1	60
160	Metabolic Surgery in a Pill. Cell Metabolism, 2017, 25, 985-987.	16.2	8
161	Diabetes-associated microbiota in fa/fa rats is modified by Roux-en-Y gastric bypass. ISME Journal, 2017, 11, 2035-2046.	9.8	52
162	Urinary sodium excretion after gastric bypass surgery. Surgery for Obesity and Related Diseases, 2017, 13, 1506-1514.	1.2	16

#	Article	IF	Citations
163	Weight Loss, Satiety, and the Postprandial Gut Hormone Response After Esophagectomy. Annals of Surgery, 2017, 266, 82-90.	4.2	47
164	Bile acid profiles over 5 years after gastric bypass and duodenal switch: results from a randomized clinical trial. Surgery for Obesity and Related Diseases, 2017, 13, 1544-1553.	1.2	47
165	What is the impact on the healthcare system if access to bariatric surgery is delayed?. Surgery for Obesity and Related Diseases, 2017, 13, 1619-1627.	1.2	30
166	Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.. Physiology and Behavior, 2017, 177, 4-12.	2.1	10
167	Elevated fasting and postprandial C-terminal telopeptide after Roux-en-Y gastric bypass. Annals of Clinical Biochemistry, 2017, 54, 495-500.	1.6	3
168	Dumping symptoms is triggered by fat as well as carbohydrates in patients operated with Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases, 2017, 13, 1159-1164.	1.2	12
169	Letter to the Editor Regarding Equivalent Increases in Circulating GLP-1 Following Jejunal Delivery of Intact and Hydrolysed Casein: Relevance to Satiety Induction following Bariatric Surgery. Obesity Surgery, 2017, 27, 816-817.	2.1	1
170	Gastrointestinal surgery for obesity and cancer: 2 sides of the same coin. Surgery for Obesity and Related Diseases, 2017, 13, 720-721.	1.2	13
171	Validated Scoring Systems for Predicting Diabetes Remission After Bariatric Surgery. Bariatric Surgical Patient Care, 2017, 12, 153-161.	0.5	1
172	Measurement of hepatic insulin sensitivity early after the bypass of the proximal small bowel in humans. Obesity Science and Practice, 2017, 3, 95-98.	1.9	7
173	Roux-En-Y Gastric Bypass in Type 2 Diabetes Patients with Mild Obesity: a Systematic Review and Meta-analysis. Obesity Surgery, 2017, 27, 2733-2739.	2.1	22
174	Do Food Preferences Change After Bariatric Surgery?. Current Atherosclerosis Reports, 2017, 19, 38.	4.8	35
175	Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/mÂ²: A Post-hoc Analysis. Obesity Facts, 2017, 10, 531-544.	3.4	27
176	Shifts in Food Preferences After Bariatric Surgery: Observational Reports and Proposed Mechanisms. Current Obesity Reports, 2017, 6, 246-252.	8.4	23
177	Effect of Roux-en-Y gastric bypass and diet-induced weight loss on diabetic kidney disease in the Zucker diabetic fatty rat. Surgery for Obesity and Related Diseases, 2017, 13, 21-27.	1.2	30
178	Renal Function and Remission of Hypertension After Bariatric Surgery: a 5-Year Prospective Cohort Study. Obesity Surgery, 2017, 27, 613-619.	2.1	38
179	The Neurobiological Impact of Ghrelin Suppression after Oesophagectomy. International Journal of Molecular Sciences, 2017, 18, 35.	4.1	3
180	Morbidity and mortality associated with obesity. Annals of Translational Medicine, 2017, 5, 161-161.	1.7	619

#	Article	IF	Citations
181	The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocrine Disorders, 2017, 17, 50.	2.2	111
182	A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. BMJ Open, 2017, 7, e018598.	1.9	13
183	Liraglutide: another reason to target prediabetes?. Oncotarget, 2017, 8, 99203-99204.	1.8	1
184	How do patients’ clinical phenotype and the physiological mechanisms of the operations impact the choice of bariatric procedure?. Clinical and Experimental Gastroenterology, 2016, Volume 9, 181-189.	2.3	3
185	The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?. Diabetes and Metabolism Journal, 2016, 40, 354.	4.7	32
186	Reconfiguration of the small intestine and diabetes remitting effects of Roux-en-Y gastric bypass surgery. Current Opinion in Gastroenterology, 2016, 32, 61-66.	2.3	6
187	Why the NHS should do more bariatric surgery; how much should we do?:. BMJ, The, 2016, 353, i1472.	6.0	78
188	Roux-en-Y gastric bypass in rats progressively decreases the proportion of fat calories selected from a palatable cafeteria diet. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R952-R959.	1.8	41
189	Type 2 diabetes with BMI<30 kg/m2: Can we predict success of metabolic surgery?. Surgery for Obesity and Related Diseases, 2016, 12, 1363-1365.	1.2	0
190	The Diabetes Surgery Summit II Guidelines: a Disease-Based Clinical Recommendation. Obesity Surgery, 2016, 26, 1989-1991.	2.1	21
191	A novel technique of Roux-en-Y gastric bypass reversal for postprandial hyperinsulinemic hypoglycaemia: A case report. International Journal of Surgery Case Reports, 2016, 21, 91-94.	0.6	16
192	Remission of type 2 diabetes in patients undergoing biliointestinal bypass for morbid obesity: a new surgical treatment. Surgery for Obesity and Related Diseases, 2016, 12, 815-821.	1.2	9
193	Hedonic Changes in Food Choices Following Roux-en-Y Gastric Bypass. Obesity Surgery, 2016, 26, 1946-1955.	2.1	27
194	Differences in Regional Brain Responses to Food Ingestion After Roux-en-Y Gastric Bypass and the Role of Gut Peptides: A Neuroimaging Study. Diabetes Care, 2016, 39, 1787-1795.	8.6	18
195	Exposureâ€“response analyses of liraglutide 3.0â€‰mg for weight management. Diabetes, Obesity and Metabolism, 2016, 18, 491-499.	4.4	52
196	Differential effects of L-tryptophan and L-leucine administration on brain resting state functional networks and plasma hormone levels. Scientific Reports, 2016, 6, 35727.	3.3	5
197	Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake. Expert Review of Endocrinology and Metabolism, 2016, 11, 475-499.	2.4	16
198	Mechanisms underpinning remission of albuminuria following bariatric surgery. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 366-372.	2.3	9

#	Article	IF	Citations
199	Changes in one-carbon metabolism after duodenal-jejunal bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E624-E632.	3.5	10
200	The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight. Current Atherosclerosis Reports, 2016, 18, 49.	4.8	19
201	Measuring changes in renal function after bariatric surgery: Why estimated glomerular filtration rate is not good enough. Surgery for Obesity and Related Diseases, 2016, 12, 1897-1898.	1.2	5
202	Capsaicin-induced satiety is associated with gastrointestinal distress but not with the release of satiety hormones. American Journal of Clinical Nutrition, 2016, 103, 305-313.	4.7	54
203	Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review. Obesity Surgery, 2016, 26, 410-421.	2.1	127
204	Food Intake and Changes in Eating Behavior After Laparoscopic Sleeve Gastrectomy. Obesity Surgery, 2016, 26, 2059-2067.	2.1	78
205	Bariatric surgery: traversing the CROSSROADS into mainstream diabetes care. Diabetologia, 2016, 59, 942-944.	6.3	1
206	Bariatric Surgery and Decreasing Vascular Risk. Angiology, 2016, 67, 610-611.	1.8	2
207	Improved glucose metabolism after gastric bypass: evolution of the paradigm. Surgery for Obesity and Related Diseases, 2016, 12, 1457-1465.	1.2	32
208	Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 599-609.	3.6	100
209	NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity. Obesity Surgery, 2016, 26, 649-659.	2.1	40
210	Equivalent Increases in Circulating GLP-1 Following Jejunal Delivery of Intact and Hydrolysed Casein: Relevance to Satiety Induction Following Bariatric Surgery. Obesity Surgery, 2016, 26, 1851-1858.	2.1	5
211	Another look at the (endoscopic duodenal liner) ENDO trial, or how to avoid the burial of a valuable antidiabetic tool. Surgery for Obesity and Related Diseases, 2016, 12, 702-704.	1.2	1
212	Impact of Duodenal-Jejunal Exclusion on Satiety Hormones. Obesity Surgery, 2016, 26, 672-678.	2.1	28
213	Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease. Obesity Surgery, 2016, 26, 1195-1202.	2.1	67
214	Glycaemic Control and Reduction of Cardiovascular Risk Following Bariatric Surgery. , 2016, , 529-534.		0
215	Mechanisms of Action of Bariatric Surgical Procedures. , 2016, , 519-527.		1
216	Which Organ is Responsible for the Pathogenesis of Obesity?. Irish Medical Journal, 2016, 109, 395.	0.0	2

#	Article	IF	Citations
217	Gut Hormone Suppression Increases Food Intake After Esophagectomy With Gastric Conduit Reconstruction. Annals of Surgery, 2015, 262, 824-830.	4.2	23
218	Roux-en-Y Gastric Bypass Surgery Increases Respiratory Quotient and Energy Expenditure during Food Intake. PLoS ONE, 2015, 10, e0129784.	2.5	30
219	Temporal changes in bile acid levels and 12Î±-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. International Journal of Obesity, 2015, 39, 806-813.	3.4	79
220	Psychological characteristics, eating behavior, and quality of life assessment of obese patients undergoing weight loss interventions. Scandinavian Journal of Surgery, 2015, 104, 10-17.	2.6	25
221	Anti-inflammatory effects of gastric bypass surgery and their association with improvement in metabolic profile. Expert Review of Endocrinology and Metabolism, 2015, 10, 435-446.	2.4	4
222	Physiological adaptations following Roux-en-Y gastric bypass and the identification of targets for bariatric mimetic pharmacotherapy. Current Opinion in Pharmacology, 2015, 25, 23-29.	3.5	7
223	Reduced sweet and fatty fluid intake after Roux-en-Y gastric bypass in rats is dependent on experience without change in stimulus motivational potency. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R864-R874.	1.8	38
224	Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 308, R321-R329.	1.8	14
225	Gastric bypass in rats does not decrease appetitive behavior towards sweet or fatty fluids despite blunting preferential intake of sugar and fat. Physiology and Behavior, 2015, 142, 179-188.	2.1	48
226	Impact of perioperative management of glycemia in severely obese diabetic patients undergoing gastric bypass surgery. Surgery for Obesity and Related Diseases, 2015, 11, 578-584.	1.2	16
227	Changes in Glucose Metabolism in Vertical Sleeve Gastrectomy. Obesity Surgery, 2015, 25, 2002-2010.	2.1	9
228	Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metabolism, 2015, 22, 228-238.	16.2	638
229	Effects of high-fat diet and gastric bypass on neurons in the caudal solitary nucleus. Physiology and Behavior, 2015, 152, 329-339.	2.1	7
230	Maternal C-reactive protein in early pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 193, 79-82.	1.1	11
231	Weight Loss Interventions and Progression of Diabetic Kidney Disease. Current Diabetes Reports, 2015, 15, 55.	4.2	16
232	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 2015, 373, 11-22.	27.0	1,492
233	Circulating Pancreatic Polypeptide Concentrations Predict Visceral and Liver Fat Content. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1048-1052.	3.6	16
234	Type 2 diabetes mellitus and microvascular complications 1Âyear after Roux-en-Y gastric bypass: a caseâ€“control study. Diabetologia, 2015, 58, 1443-1447.	6.3	67

#	Article	IF	Citations
235	Cardiovascular, Renal and Overall Health Outcomes After Bariatric Surgery. Current Cardiology Reports, 2015, 17, 34.	2.9	10
236	Five-Year Outcomes After Laparoscopic Gastric Bypass and Laparoscopic Duodenal Switch in Patients With Body Mass Index of 50 to 60. JAMA Surgery, 2015, 150, 352.	4.3	177
237	How long should we make the biliopancreatic limb during Roux-en-Y gastric bypass?. Surgery for Obesity and Related Diseases, 2015, 11, 1246-1247.	1.2	4
238	Changes in Reward after Gastric Bypass: the Advantages and Disadvantages. Current Atherosclerosis Reports, 2015, 17, 61.	4.8	13
239	Metabolic phenotype-microRNA data fusion analysis of the systemic consequences of Roux-en-Y gastric bypass surgery. International Journal of Obesity, 2015, 39, 1126-1134.	3.4	30
240	Type 2 diabetes: multimodal treatment of a complex disease. Lancet, The, 2015, 386, 936-937.	13.7	20
241	Copper, selenium and zinc levels after bariatric surgery in patients recommended to take multivitamin-mineral supplementation. Journal of Trace Elements in Medicine and Biology, 2015, 31, 167-172.	3.0	59
242	Predicting refeeding hypophosphataemia: insulin growth factor 1 (IGF-1) as a diagnostic biochemical marker for clinical practice. Annals of Clinical Biochemistry, 2015, 52, 82-87.	1.6	26
243	Aspartame Sensitivity? A Double Blind Randomised Crossover Study. PLoS ONE, 2015, 10, e0116212.	2.5	11
244	Roux-en-Y Gastric Bypass Surgery Induces Early Plasma Metabolomic and Lipidomic Alterations in Humans Associated with Diabetes Remission. PLoS ONE, 2015, 10, e0126401.	2.5	66
245	Truncating Homozygous Mutation of Carboxypeptidase E (CPE) in a Morbidly Obese Female with Type 2 Diabetes Mellitus, Intellectual Disability and Hypogonadotrophic Hypogonadism. PLoS ONE, 2015, 10, e0131417.	2.5	72
246	Endogenous Glucagon-Like Peptide-1 as a Potential Mediator of the Resolution of Diabetic Kidney Disease following Roux en Y Gastric Bypass: Evidence and Perspectives. Advances in Endocrinology, 2014, 2014, 1-11.	0.1	1
247	Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?. International Journal of Obesity, 2014, 38, 325-333.	3.4	53
248	The role of bariatric surgery in the treatment of diabetes. Therapeutic Advances in Chronic Disease, 2014, 5, 149-157.	2.5	20
249	Bone mineral density and expression of vitamin D receptor-dependent calcium uptake mechanisms in the proximal small intestine after bariatric surgery. British Journal of Surgery, 2014, 101, 1566-1575.	0.3	25
250	Improvements in the metabolic milieu following Rouxâ€enâ€Y gastric bypass and the arrest of diabetic kidney disease. Experimental Physiology, 2014, 99, 1146-1153.	2.0	20
251	Application of the International Diabetes Federation and American Diabetes Association criteria in the assessment of metabolic control after bariatric surgery. Diabetes, Obesity and Metabolism, 2014, 16, 86-89.	4.4	23
252	The physiology of altered eating behaviour after Rouxâ€enâ€Y gastric bypass. Experimental Physiology, 2014, 99, 1128-1132.	2.0	47

#	Article	IF	Citations
253	Physiological and pathophysiological signalling between the gut and the kidney: role in diabetic kidney disease. Experimental Physiology, 2014, 99, 1138-1139.	2.0	2
254	Bariatric Surgery and Microvascular Complications of Type 2 Diabetes Mellitus. Current Atherosclerosis Reports, 2014, 16, 453.	4.8	27
255	Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. Gut, 2014, 63, 891-902.	12.1	234
256	Rats Fed Diets with Different Energy Contribution from Fat Do Not Differ in Adiposity. Obesity Facts, 2014, 7, 302-310.	3.4	9
257	Where to Begin and Where to End? Preoperative Assessment for Patients Undergoing Metabolic Surgery. Digestive Surgery, 2014, 31, 25-32.	1.2	5
258	Can we predict diabetes remission after weight-loss surgery?. Lancet Diabetes and Endocrinology,the, 2014, 2, 4-6.	11.4	4
259	Beyond Weight Loss: Evaluating the Multiple Benefits of Bariatric Surgery After Roux-en-Y Gastric Bypass and Adjustable Gastric Band. Obesity Surgery, 2014, 24, 684-691.	2.1	24
260	Duodenal-Jejunal Bypass and Jejunectomy Improve Insulin Sensitivity in Goto-Kakizaki Diabetic Rats Without Changes in Incretins or Insulin Secretion. Diabetes, 2014, 63, 1069-1078.	0.6	51
261	The Effect of Bariatric Surgery on Intestinal Absorption and Transit Time. Obesity Surgery, 2014, 24, 796-805.	2.1	96
262	Bariatric Surgery: The Indications in Metabolic Disease. Digestive Surgery, 2014, 31, 6-12.	1.2	13
263	The gutâ€“brain axis in obesity. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 559-571.	2.4	59
264	Roux-en Y Gastric Bypass Is Superior to Duodeno-Jejunal Bypass in Improving Glycaemic Control in Zucker Diabetic Fatty Rats. Obesity Surgery, 2014, 24, 1888-1895.	2.1	21
265	Intestinal sweet-sensing pathways and metabolic changes after Roux-en-Y gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2014, 307, G588-G593.	3.4	23
266	More symptoms but similar blood glucose curve after oral carbohydrate provocation in patients with a history of hypoglycemia-like symptoms compared to asymptomatic patients after Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases, 2014, 10, 1047-1054.	1.2	32
267	Preoperative assessment of gut hormones does not correlate to weight loss after Roux-en-Y gastric bypass surgery. Surgery for Obesity and Related Diseases, 2014, 10, 822-828.	1.2	9
268	Body mass index and diabetes status do not affect postoperative infection rates after bariatric surgery. Surgery for Obesity and Related Diseases, 2014, 10, 291-297.	1.2	16
269	Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. Lancet Diabetes and Endocrinology,the, 2014, 2, 141-151.	11.4	31
270	Improving patient waiting times: a simulation study of an obesity care service. BMJ Quality and Safety, 2014, 23, 373-381.	3.7	19

#	Article	IF	Citations
271	Urine Bile Acids Relate to Glucose Control in Patients with Type 2 Diabetes Mellitus and a Body Mass Index Below 30 kg/m2. PLoS ONE, 2014, 9, e93540.	2.5	26
272	The Controversies Around Roux-en-Y Gastric Bypass. , 2014, , 253-261.		0
273	Mechanisms of Bariatric Surgery. , 2014, , 137-148.		0
274	Metabolic Effects of Bariatric Surgery: A Focus on Inflammation and Diabetic Kidney Disease. Current Obesity Reports, 2013, 2, 120-127.	8.4	2
275	Mechanisms underlying weight loss after bariatric surgery. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 575-584.	17.8	267
276	Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. BMC Medicine, 2013, 11, 8.	5.5	111
277	Effects of preoperative exposure to a high-fat versus a low-fat diet on ingestive behavior after gastric bypass surgery in rats. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 4192-4201.	2.4	36
278	Endoscopic Duodenalâ€"Jejunal Bypass Liner Rapidly Improves Type 2 Diabetes. Obesity Surgery, 2013, 23, 1354-1360.	2.1	136
279	Changes in gut hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy. Surgery for Obesity and Related Diseases, 2013, 9, 192-201.	1.2	59
280	Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scandinavian Journal of Gastroenterology, 2013, 48, 1257-1264.	1.5	71
281	Role of proximal gut exclusion from food on glucose homeostasis in patients with Type 2 diabetes. Diabetic Medicine, 2013, 30, 1482-1486.	2.3	40
282	Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surgery for Obesity and Related Diseases, 2013, 9, 559-568.	1.2	117
283	Adherence to the national institute of clinical excellence guidance on parenteral nutrition screening is not enough to improve outcomes. Clinical Nutrition, 2013, 32, 73-76.	5.0	4
284	Fast-track laparoscopic bariatric surgery: a systematic review. Updates in Surgery, 2013, 65, 85-94.	2.0	63
285	Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine. Physiology and Behavior, 2013, 119, 92-96.	2.1	83
286	Urinary Phenotyping Indicates Weight Loss-Independent Metabolic Effects of Roux-en-Y Gastric Bypass in Mice. Journal of Proteome Research, 2013, 12, 1245-1253.	3.7	16
287	Bariatric surgery: a best practice article. Journal of Clinical Pathology, 2013, 66, 90-98.	2.0	47
288	The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation. Nephrology Dialysis Transplantation, 2013, 28, iv73-iv82.	0.7	33

#	Article	IF	Citations
289	Are Bile Acids the New Gut Hormones? Lessons From Weight Loss Surgery Models. Endocrinology, 2013, 154, 2255-2256.	2.8	39
290	Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Annals of Clinical Biochemistry, 2013, 50, 360-364.	1.6	68
291	Duodenalâ€“jejunal bypass liners. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 420-428.	2.3	5
292	Incretins: new targets for the prevention of diabetes and obesity. Clinical Lipidology, 2013, 8, 109-121.	0.4	1
293	Twenty-Four Hour Energy Expenditure and Skeletal Muscle Gene Expression Changes After Bariatric Surgery. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E321-E327.	3.6	20
294	Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabetic Medicine, 2013, 30, 1495-1499.	2.3	58
295	Gastric bypass surgery alters food preferences through changes in the perception of taste. Clinical Practice (London, England), 2013, 10, 471-479.	0.1	5
296	Increased Postprandial Energy Expenditure May Explain Superior Long Term Weight Loss after Roux-en-Y Gastric Bypass Compared to Vertical Banded Gastroplasty. PLoS ONE, 2013, 8, e60280.	2.5	78
297	Effect of vertical sleeve gastrectomy in melanocortin receptor 4-deficient rats. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E103-E110.	3.5	41
298	Bariatric Surgery Does Not Exacerbate and May Be Beneficial for the Microvascular Complications of Type 2 Diabetes. Diabetes Care, 2012, 35, e81-e81.	8.6	63
299	Improved blood pressure, nitric oxide and asymmetric dimethylarginine are independent after bariatric surgery. Annals of Clinical Biochemistry, 2012, 49, 589-594.	1.6	7
300	Roux-en-Y gastric bypass in rats increases sucrose taste-related motivated behavior independent of pharmacological GLP-1-receptor modulation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R751-R767.	1.8	62
301	GLP-1 and Glucagon Secretion from a Pancreatic Neuroendocrine Tumor Causing Diabetes and Hyperinsulinemic Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3039-3045.	3.6	25
302	The Role of Bile After Roux-en-Y Gastric Bypass in Promoting Weight Loss and Improving Glycaemic Control. Endocrinology, 2012, 153, 3613-3619.	2.8	343
303	Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task. American Journal of Clinical Nutrition, 2012, 96, 467-473.	4.7	146
304	Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. International Journal of Obesity, 2012, 36, 379-384.	3.4	44
305	Increased Energy Expenditure in Gastric Bypass Rats Is Not Caused by Activated Brown Adipose Tissue. Obesity Facts, 2012, 5, 349-358.	3.4	20
306	Roux-en-Y Gastric Bypass Operation in Rats. Journal of Visualized Experiments, 2012, , e3940.	0.3	28

#	Article	IF	Citations
307	Bariatric surgery for type 2 diabetes. Lancet, The, 2012, 379, 2300-2311.	13.7	263
308	Mechanisms of Weight Loss, Diabetes Control and Changes in Food Choices After Gastrointestinal Surgery. Current Atherosclerosis Reports, 2012, 14, 616-623.	4.8	20
309	Long-term results of a randomized clinical trial comparing Roux-en-Y gastric bypass with vertical banded gastroplasty. British Journal of Surgery, 2012, 100, 222-230.	0.3	37
310	Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures. Thorax, 2012, 67, 442-449.	5.6	87
311	Cerebral Markers of the Serotonergic System in Rat Models of Obesity and After Rouxâ€enâ€Y Gastric Bypass. Obesity, 2012, 20, 2133-2141.	3.0	24
312	Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. Surgery for Obesity and Related Diseases, 2012, 8, 371-374.	1.2	55
313	Gut Hormones and Leptin: Impact on Energy Control and Changes After Bariatric Surgeryâ€"What the Future Holds. Obesity Surgery, 2012, 22, 1648-1657.	2.1	38
314	Bariatric surgery: a European perspective. European Diabetes Nursing, 2012, 9, 22-25.	0.2	0
315	Roux-en-Y Gastric Bypass in Miceâ€"Surgical Technique and Characterisation. Obesity Surgery, 2012, 22, 1117-1125.	2.1	20
316	Molecular mechanisms underlying bile acidâ€stimulated glucagonâ€like peptideâ€1 secretion. British Journal of Pharmacology, 2012, 165, 414-423.	5.4	179
317	High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver International, 2012, 32, 128-136.	3.9	46
318	Can a Protocol for Glycaemic Control Improve Type 2 Diabetes Outcomes After Gastric Bypass?. Obesity Surgery, 2012, 22, 90-96.	2.1	32
319	Changes in Gastrointestinal Hormones and Leptin After Rouxâ€enâ€Y Gastric Bypass Surgery. Journal of Parenteral and Enteral Nutrition, 2011, 35, 169-180.	2.6	70
320	Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut, 2011, 60, 1214-1223.	12.1	391
321	Sodium and water handling after gastric bypass surgery in a rat model. Surgery for Obesity and Related Diseases, 2011, 7, 68-73.	1.2	25
322	Gastrointestinal hormones, energy balance and bariatric surgery. International Journal of Obesity, 2011, 35, S35-S39.	3.4	47
323	Experimental bariatric surgery in rats generates a cytotoxic chemical environment in the gut contents. Frontiers in Microbiology, 2011, 2, 183.	3.5	62
324	Adherence to the National Institute of Clinical Excellence guidance on parenteral nutrition screening is not adequate to improve outcomes. Proceedings of the Nutrition Society, 2011, 70, .	1.0	0

#	Article	IF	Citations
325	The relationship between postprandial bile acid concentration, GLPâ€1, PYY and ghrelin. Clinical Endocrinology, 2011, 74, 67-72.	2.4	61
326	Alterations of sucrose preference after Roux-en-Y gastric bypass. Physiology and Behavior, 2011, 104, 709-721.	2.1	158
327	Pancreatic Polypeptide Meal Response May Predict Gastric Band-Induced Weight Loss. Obesity Surgery, 2011, 21, 1906-1913.	2.1	12
328	Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. British Journal of Surgery, 2011, 99, 100-103.	0.3	165
329	Heart remodelling and obesity: the complexities and variation of cardiac geometry. Heart, 2011, 97, 171-172.	2.9	43
330	Lessons Learned from Gastric Bypass Operations in Rats. Obesity Facts, 2011, 4, 3-12.	3.4	41
331	Leptin and insulin growth factor 1: diagnostic markers of the refeeding syndrome and mortality. British Journal of Nutrition, 2011, 106, 906-912.	2.3	17
332	Gastric bypass reduces fat intake and preference. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R1057-R1066.	1.8	207
333	Leptin/adiponectin ratio in patients with coronary heart disease: comparing subjects with and without metabolic syndrome. Annals of Clinical Biochemistry, 2011, 48, 327-331.	1.6	15
334	The Role of Bile Acids in Gut-Hormone-Induced Weight Loss After Bariatric Surgery: Implications for Appetite Control and Diabetes. , 2011, , 1317-1330.		2
335	Remission of Type 2 Diabetes After Gastric Bypass and Banding. Annals of Surgery, 2010, 252, 966-971.	4.2	207
336	Bariatric surgery and taste: novel mechanisms of weight loss. Current Opinion in Gastroenterology, 2010, 26, 140-145.	2.3	132
337	Gut Hypertrophy After Gastric Bypass Is Associated With Increased Glucagon-Like Peptide 2 and Intestinal Crypt Cell Proliferation. Annals of Surgery, 2010, 252, 50-56.	4.2	153
338	Upper gastrointestinal investigations before gastric banding. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 1025-1030.	2.4	17
339	The Gut Hormone Response Following Roux-en-Y Gastric Bypass: Cross-sectional and Prospective Study. Obesity Surgery, 2010, 20, 56-60.	2.1	75
340	Vagal Sparing Surgical Technique but Not Stoma Size Affects Body Weight Loss in Rodent Model of Gastric Bypass. Obesity Surgery, 2010, 20, 616-622.	2.1	81
341	Renal cytokines improve early after bariatric surgery. British Journal of Surgery, 2010, 97, 1838-1844.	0.3	43
342	Influence of adherence to the national guidance on nutrition screening and dietitian referral on clinical outcomes of those requiring parenteral nutrition. Journal of Human Nutrition and Dietetics, 2010, 23, 190-193.	2.5	5

#	Article	IF	Citations
343	Assessment of serumâ€free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical Endocrinology, 2010, 72, 305-311.	2.4	30
344	Effect of rimonabant and metformin on glucoseâ€dependent insulinotropic polypeptide and glucagonâ€like peptideâ€1 in obese women with polycystic ovary syndrome. Clinical Endocrinology, 2010, 72, 423-425.	2.4	4
345	Ghrelin and Metabolic Surgery. International Journal of Peptides, 2010, 2010, 1-5.	0.7	38
346	Postprandial plasma bile acid responses in normal weight and obese subjects. Annals of Clinical Biochemistry, 2010, 47, 482-484.	1.6	82
347	Postprandial bone turnover is independent of calories above 250 kcal. Annals of Clinical Biochemistry, 2010, 47, 318-320.	1.6	11
348	Gastric Bypass Increases Energy Expenditure in Rats. Gastroenterology, 2010, 138, 1845-1853.e1.	1.3	195
349	Eating Slowly Increases the Postprandial Response of the Anorexigenic Gut Hormones, Peptide YY and Glucagon-Like Peptide-1. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 333-337.	3.6	204
350	The role of bariatric surgery in the management of female fertility. Human Fertility, 2010, 13, 67-71.	1.7	13
351	Mechanisms of Weight Loss after Gastric Bypass and Gastric Banding. Obesity Facts, 2009, 2, 325-331.	3.4	33
352	When the Brakes Came Off: Re-feeding Oedema after Deflation of a Gastric Band: A Case Report. Obesity Surgery, 2009, 19, 1468-1470.	2.1	8
353	Obesity, Gut Hormones, and Bariatric Surgery. World Journal of Surgery, 2009, 33, 1983-1988.	1.6	56
354	After bariatric surgery, what vitamins should be measured and what supplements should be given?. Clinical Endocrinology, 2009, 71, 322-325.	2.4	50
355	The mechanisms of weight loss after bariatric surgery. International Journal of Obesity, 2009, 33, S28-S32.	3.4	82
356	Metabolic surgery and gut hormones â€“ A review of bariatric entero-humoral modulation. Physiology and Behavior, 2009, 97, 620-631.	2.1	92
357	A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid Biosynthesis. Clinical Gastroenterology and Hepatology, 2009, 7, 1189-1194.	4.4	280
358	Serum total cortisol and free cortisol index give different information regarding the hypothalamusâ€“pituitaryâ€“adrenal axis reserve in patients with liver impairment. Annals of Clinical Biochemistry, 2009, 46, 505-507.	1.6	32
359	Bariatric surgery and hypertension. Surgery for Obesity and Related Diseases, 2009, 5, 615-620.	1.2	30
360	Sir David Cuthbertson Medal Lecture Bariatric surgery as a model to study appetite control. Proceedings of the Nutrition Society, 2009, 68, 227-233.	1.0	8

#	Article	IF	Citations
361	Changes in gut hormones after bariatric surgery. Clinical Endocrinology, 2008, 69, 173-179.	2.4	83
362	Mechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 268-277.	1.7	57
363	The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion. Appetite, 2008, 51, 747-750.	3.7	39
364	The satiety hormone peptide YY as a regulator of appetite. Journal of Clinical Pathology, 2008, 61, 548-552.	2.0	41
365	Effects of Bariatric Surgery on Cardiovascular Function. Circulation, 2008, 118, 2091-2102.	1.6	211
366	Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Annals of Clinical Biochemistry, 2008, 45, 93-95.	1.6	53
367	The impact of 2006 guidance on nutrition support, in clinical outcome measures. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
368	The impact of 2006 guidance on nutrition support, in clinical outcome measures. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
369	Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass. Annals of Surgery, 2007, 246, 780-785.	4.2	622
370	Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin. American Journal of Clinical Nutrition, 2007, 85, 967-971.	4.7	179
371	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. American Journal of Clinical Nutrition, 2007, 86, 1603-1610.	4.7	76
372	Could a virus contribute to weight gain?. International Journal of Obesity, 2007, 31, 1350-1356.	3.4	25
373	New agents in development for the management of obesity. International Journal of Clinical Practice, 2007, 61, 2103-2112.	1.7	15
374	Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obesity Surgery, 2007, 17, 1193-1198.	2.1	51
375	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. American Journal of Clinical Nutrition, 2007, 86, 1603-1610.	4.7	30
376	Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obesity Surgery, 2007, 17, 1193-1198.	2.1	2
377	Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metabolism, 2006, 4, 223-233.	16.2	501
378	Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters. Annals of Surgery, 2006, 243, 108-114.	4.2	861

#	Article	IF	Citations
379	The longest-surviving patient with classical maple syrup urine disease. Journal of Inherited Metabolic Disease, 2006, 29, 190-194.	3.6	2
380	The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients. Clinical Nutrition, 2006, 25, 626-633.	5.0	34
381	Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. British Journal of Surgery, 2006, 93, 210-215.	0.3	289
382	Attenuated Peptide YY Release in Obese Subjects Is Associated with Reduced Satiety. Endocrinology, 2006, 147, 3-8.	2.8	466
383	The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. Heart, 2005, 91, 241-242.	2.9	36
384	Postprandial Plasma Ghrelin Is Suppressed Proportional to Meal Calorie Content in Normal-Weight But Not Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1068-1071.	3.6	243
385	Ghrelin Does Not Stimulate Food Intake in Patients with Surgical Procedures Involving Vagotomy. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4521-4524.	3.6	243
386	Why Do Patients Lose Weight after Roux-en-Y Gastric Bypass?. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 591-592.	3.6	39
387	Peptide YY, appetite and food intake. Proceedings of the Nutrition Society, 2005, 64, 213-216.	1.0	95
388	Characterization of Ghrelin-Like Immunoreactivity in Human Plasma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2205-2211.	3.6	146
389	A new antiglycolytic agent. Annals of Clinical Biochemistry, 2004, 41, 43-46.	1.6	14
390	Free Cortisol Index Is Better Than Serum Total Cortisol in Determining Hypothalamic-Pituitary-Adrenal Status in Patients Undergoing Surgery. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2045-2048.	3.6	121
391	Inhibition of Food Intake in Obese Subjects by Peptide YY_{3â€“36}. New England Journal of Medicine, 2003, 349, 941-948.	27.0	1,423
392	Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4696-4701.	3.6	406
393	Pancreatic Polypeptide Reduces Appetite and Food Intake in Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3989-3992.	3.6	427
394	Clinical authorization: what is best for the patient?. Annals of Clinical Biochemistry, 2003, 40, 113-114.	1.6	2
395	Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment?. Annals of Clinical Biochemistry, 2002, 39, 148-150.	1.6	65
396	Free cortisol index as a surrogate marker for serum free cortisol. Annals of Clinical Biochemistry, 2002, 39, 406-408.	1.6	81

#	Article	IF	Citations
397	A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic. Clinical Therapeutics, 2002, 24, 1154-1160.	2.5	10
398	Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery. , 0, , 105-116.		0